Source: HVMN

13 days after publishing a paper on hydroxychloroquine (a potential drug for coronavirus treatment), The Lancet retracted the study due to faulty data. 

In the midst of a global pandemic, the study (that have since been retracted) was used as a basis for the guidelines set by the WHO, the CDC, elected officials, and…well, let’s see how deep this rabbit hole leads us by the man who helped break the story.

Our guest today, James Todaro, MD, played a significant role in this multi-layered scandal: By revealing the red flags of a study published by one of the world’s oldest and best-known medical journals, and causing The Lancet to retract it in just 13 days.

Buckle up and enjoy this episode of the H.V.M.N. Podcast. You can follow Dr. Todaro on Twitter and his ongoing work here 👉

Related: Dr James Todaro: An Effective Treatment for Coronavirus (COVID-19) – Previously Censored.

Why That Observational Study of Hydroxychloroquine in The Lancet Seems Fishy

LancetGate: Surgisphere – is the company which provided the data to the study serious?

Lancet HCQ, A Study Out of Thin Air

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

American Hero: Ralph C. Lorigo Fights for Client Rights Including Access to Ivermectin for COVID-19 Patients At Risk

Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.

Read More »